Increasing_VBG Incidence_NN of_IN Candidemia_NP :_: Results_NNS from_IN a_DT 20-Year_JJ Nationwide_NP Study_NP in_IN Iceland_NP A_DT nationwide_JJ study_NN on_IN candidemia_NN was_VBD conducted_VBN in_IN Iceland_NP from_IN 1980_CD to_TO 1999_CD ._SENT The_DT annual_JJ incidence_NN increased_VBN from_IN 1.4_CD cases/100,000_NN inhabitants/year_NN between_IN 1980_CD and_CC 1984_CD to_TO 4.9_CD cases/100,000_NN inhabitants/year_NN between_IN 1995_CD and_CC 1999_CD (_( P_NN <_SYM 0.0001_CD )_) ._SENT Candidemia_NN episodes_NNS at_IN university_NN hospitals_NNS increased_VBN from_IN 0.15/1,000_CD admissions_NNS to_TO 0.55/1,000_CD admissions_NNS (_( P_NN <_SYM 0.0001_CD )_) ._SENT Candida_NP albicans_NNS was_VBD the_DT predominant_JJ species_NNS responsible_JJ (_( 64.4_CD %_NN )_) ._SENT The_DT national_JJ import_NN of_IN fluconazole_NN increased_VBD approximately_RB fourfold_RB during_IN the_DT second_JJ half_NN of_IN the_DT study_NN ,_, but_CC increased_VBD resistance_NN to_TO this_DT agent_NN was_VBD not_RB observed_VBN ._SENT The_DT incidence_NN of_IN invasive_JJ fungal_JJ infections_NNS is_VBZ increasing_VBG in_IN many_JJ hospitals_NNS ._SENT The_DT National_NP Nosocomial_NP Infections_NP Surveillance_NP (_( NNIS_NP )_) program_NN for_IN U.S._NP hospitals_NNS documented_VBD a_DT doubling_NN in_IN the_DT rate_NN of_IN nosocomial_JJ fungal_JJ infections_NNS between_IN 1980_CD and_CC 1990_CD ._SENT From_IN 1995_CD to_TO 1996_CD ,_, Candida_NP species_NNS was_VBD the_DT fourth_JJ most_RBS common_JJ cause_NN of_IN nosocomial_JJ bloodstream_NN infections_NNS (_( BSIs_NP )_) in_IN the_DT United_NP States_NPS ._SENT In_IN recent_JJ years_NNS ,_, some_DT studies_NNS have_VBP reported_VBN an_DT increase_NN of_IN candidemia_NN due_JJ to_TO Candida_NP non-albicans_NP species_NNS ,_, with_IN the_DT threat_NN of_IN increased_VBN mortality_NN and_CC antifungal_JJ drug_NN resistance_NN ._SENT The_DT epidemiology_NN of_IN candidemia_NN has_VBZ been_VBN studied_VBN primarily_RB in_IN selected_JJ hospitals_NNS ;_: few_JJ studies_NNS have_VBP focused_VBN on_IN this_DT problem_NN on_IN a_DT nationwide_JJ basis_NN ._SENT The_DT purpose_NN of_IN this_DT study_NN was_VBD to_TO examine_VB candidemia_NN in_IN Iceland_NP during_IN a_DT 20-year_JJ period_NN with_IN respect_NN to_TO epidemiology_NN and_CC clinical_JJ mycology_NN ._SENT Due_JJ to_TO the_DT high_JJ quality_NN and_CC accessibility_NN of_IN demographic_JJ and_CC medical_JJ data_NNS ,_, Iceland_NP ,_, a_DT 103,000-km2_JJ island_NN in_IN the_DT north_JJ Atlantic_JJ ocean_NN with_IN 285,000_CD inhabitants_NNS ,_, is_VBZ well_RB suited_VBN for_IN epidemiological_JJ studies_NNS ._SENT All_DT patients_NNS in_IN Iceland_NP with_IN yeast_NN isolated_VBN from_IN blood_NN from_IN 1_CD January_NP 1980_CD to_TO 31_CD December_NP 1999_CD were_VBD identified_VBN retrospectively_RB by_IN a_DT nationwide_JJ search_NN in_IN microbiology_NN databases_NNS ._SENT During_IN the_DT first_JJ decade_NN of_IN the_DT study_NN ,_, a_DT Bactec_NP (_( Becton_NP Dickinson_NP Microbiology_NP Systems_NPS )_) radiometric_JJ system_NN was_VBD most_RBS widely_RB used_VBN ._SENT During_IN the_DT second_JJ decade_NN of_IN the_DT study_NN ,_, the_DT nonradiometric_JJ systems_NNS Bactec_NP ,_, Difco_NP ESP_NP (_( Becton_NP Dickinson_NP )_) ,_, and_CC bioMerieux_NP Vital_NP (_( bioMerieux_NP )_) were_VBD used_VBN ._SENT There_EX are_VBP 2_CD university_NN or_CC university-affiliated_JJ hospitals_NNS and_CC 14_CD county_NN hospitals_NNS in_IN the_DT country_NN ._SENT Three_CD clinical_JJ microbiology_NN laboratories_NNS process_VBP blood_NN cultures_NNS from_IN all_DT of_IN the_DT hospitals_NNS ._SENT An_DT episode_NN of_IN yeast_NN BSI_NP was_VBD defined_VBN as_IN at_IN least_JJS one_CD blood_NN culture_NN positive_JJ for_IN yeast_NN ._SENT Episodes_NNS were_VBD considered_VBN separate_JJ if_IN they_PP occurred_VBD more_JJR than_IN 2_CD weeks_NNS apart_RB ._SENT Viable_JJ yeast_NN BSIs_NN were_VBD subcultured_VBN on_IN Sabouraud_NP agar_NN (_( Oxoid_NP )_) ._SENT Species_NP identification_NN was_VBD based_VBN on_IN germ_NN tube_NN production_NN ,_, distinctive_JJ color_NN ,_, and_CC morphology_NN on_IN CHROMagar_NP (_( Hardy_NP Diagnostics_NP )_) and_CC sugar_NN assimilation_NN profiles_NNS by_IN using_VBG the_DT API_NP id32C_NN system_NN (_( bioMerieux_NNS )_) ._SENT The_DT MICs_NP of_IN amphotericin_NP B_NP ,_, fluconazole_NN ,_, and_CC itraconazole_NN were_VBD determined_VBN by_IN using_VBG an_DT Etest_NP (_( AB_NP Biodisk_NP )_) according_VBG to_TO instructions_NNS from_IN the_DT manufacturer_NN (_( Antifungal_JJ susceptibility_NN testing_NN of_IN yeasts_NNS ,_, Etest_JJ technical_JJ guide_NN 4_CD ,_, AB_NP Biodisk_NP ,_, Solna_NP ,_, Sweden_NP ,_, 1997_CD )_) ._SENT The_DT plates_NNS were_VBD incubated_VBN at_IN 35C_JJ for_IN 48_CD h_NN before_IN reading_VBG the_DT MICs_NP ._SENT The_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NP (_( NCCLS_NP )_) breakpoint_NN criteria_NNS for_IN antifungal_JJ susceptibility_NN were_VBD used_VBN ._SENT National_JJ import_NN figures_NNS on_IN antifungal_JJ agents_NNS for_IN the_DT period_NN from_IN 1980_CD to_TO 1999_CD were_VBD obtained_VBN from_IN the_DT Icelandic_JJ Association_NP of_IN Importers_NP of_IN Pharmaceuticals_NPS ._SENT The_DT number_NN of_IN defined_VBN daily_JJ doses_NNS (_( DDD_NP )_) per_IN packing_NN was_VBD calculated_VBN ,_, and_CC the_DT import_NN was_VBD expressed_VBN as_IN DDD_NN per_IN 1,000_CD inhabitants_NNS per_IN year_NN ._SENT Information_NN about_IN national_JJ demographics_NNS ,_, including_VBG age_NN distribution_NN ,_, for_IN the_DT period_NN from_IN 1980_CD to_TO 1999_CD was_VBD obtained_VBN from_IN the_DT Bureau_NP of_IN Statistics_NPS in_IN Iceland_NP ._SENT Information_NN on_IN admissions_NNS to_TO pediatric_JJ ,_, medical_JJ ,_, and_CC surgical_JJ wards_NNS at_IN the_DT university_NN hospitals_NNS for_IN each_DT year_NN of_IN the_DT study_NN was_VBD obtained_VBN from_IN annual_JJ hospital_NN reports_NNS ._SENT The_DT chi-square_NN test_NN for_IN linear_JJ trend_NN was_VBD used_VBN to_TO compare_VB incidence_NN rates_NNS between_IN study_NN periods_NNS ,_, and_CC the_DT chi-square_NN test_NN was_VBD used_VBN to_TO compare_VB fungal_JJ species_NN distribution_NN and_CC proportions_NNS of_IN blood_NN cultures_NNS positive_JJ for_IN yeasts_NNS between_IN the_DT first_JJ and_CC second_JJ halves_NNS of_IN the_DT study_NN period_NN ._SENT In_IN the_DT 20-year_JJ period_NN from_IN 1980_CD to_TO 1999_CD ,_, 172_CD episodes_NNS of_IN BSI_NP with_IN yeasts_NNS ,_, predominantly_RB candidemia_NN ,_, were_VBD diagnosed_VBN in_IN 165_CD patients_NNS in_IN Iceland_NP ._SENT Children_NP (_( <=16_NN years_NNS )_) comprised_VBN 11_CD (_( 7_CD %_NN )_) of_IN the_DT patients_NNS ,_, and_CC adults_NNS comprised_VBD 154_CD (_( 93_CD %_NN )_) of_IN the_DT patients_NNS ._SENT Six_CD patients_NNS had_VBD two_CD or_CC more_JJR separate_JJ episodes_NNS ,_, occurring_VBG at_IN least_JJS 2_CD weeks_NNS apart_RB ._SENT The_DT nationwide_JJ annual_JJ incidence_NN of_IN candidemia_NN and_CC number_NN of_IN candidemic_JJ episodes_NNS per_IN 1,000_CD admissions_NNS to_TO the_DT university_NN hospitals_NNS is_VBZ shown_VBN in_IN Fig._NN ._SENT A_DT vast_JJ majority_NN of_IN the_DT patients_NNS (_( 87_CD %_NN )_) came_VBD from_IN the_DT university_NN hospitals_NNS ._SENT Figure_NN shows_VBZ the_DT age-specific_JJ incidence_NN for_IN the_DT first_JJ and_CC second_JJ halves_NNS of_IN the_DT observation_NN period_NN ,_, respectively_RB ._SENT During_IN the_DT second_JJ decade_NN of_IN the_DT study_NN ,_, the_DT use_NN of_IN blood_NN cultures_NNS at_IN the_DT two_CD university_NN hospitals_NNS increased_VBN from_IN 71,002_CD vials_NNS between_IN 1990_CD and_CC 1994_CD to_TO 93,032_CD between_IN 1995_CD and_CC 1999_CD ._SENT The_DT proportion_NN of_IN blood_NN cultures_NNS positive_JJ for_IN yeasts_NNS increased_VBN slightly_RB ,_, from_IN 0.187_CD %_NN between_IN 1990_CD and_CC 1994_CD to_TO 0.204_CD %_NN between_IN 1995_CD and_CC 1999_CD ,_, but_CC this_DT increase_NN was_VBD not_RB significant_JJ (_( P_NN =_SYM 0.464_CD )_) ._SENT FIG._NN 1_CD ._SENT |_SYM Increasing_VBG incidence_NN (_( cases/100,000_JJ inhabitants/year_NN )_) of_IN candidemia_NN in_IN Iceland_NP during_IN a_DT 20-year_JJ period_NN ,_, from_IN 1980_CD to_TO 1999_CD ._SENT Increasing_VBG incidence_NN (_( cases/100,000_JJ inhabitants/year_NN )_) of_IN candidemia_NN in_IN Iceland_NP during_IN a_DT 20-year_JJ period_NN ,_, from_IN 1980_CD to_TO 1999_CD ._SENT The_DT open_JJ squares_NNS with_IN solid_JJ lines_NNS represent_VBP the_DT population-based_JJ incidence_NN ,_, whereas_IN the_DT filled_VBN squares_NNS with_IN dashed_VBN lines_NNS depict_VBP the_DT incidence_NN as_IN a_DT proportion_NN of_IN 1,000_CD admissions_NNS to_TO the_DT university_NN hospitals_NNS in_IN the_DT country_NN ._SENT As_IN shown_VBN ,_, the_DT nationwide_JJ incidence_NN increased_VBD 3.5-fold_NN during_IN the_DT 20_CD years_NNS of_IN the_DT study_NN ,_, from_IN 1.4_CD between_IN 1980_CD and_CC 1984_CD to_TO 4.9_CD between_IN 1995_CD and_CC 1999_CD (_( P_NN <_SYM 0.0001_CD )_) ._SENT The_DT number_NN of_IN candidemic_JJ episodes_NNS per_IN 1,000_CD admissions_NNS at_IN the_DT two_CD university_NN hospitals_NNS also_RB increased_VBD significantly_RB ,_, from_IN 0.15/1,000_CD admissions_NNS between_IN 1980_CD and_CC 1984_CD to_TO 0.55/1,000_CD admissions_NNS between_IN 1995_CD and_CC 1999_CD (_( P_NN <_SYM 0.0001_CD )_) ._SENT FIG._NN 2_CD ._SENT |_SYM Age-specific_JJ incidence_NN of_IN fungal_JJ BSIs_NN in_IN Iceland_NP from_IN 1980_CD to_TO 1999_CD calculated_VBN for_IN the_DT first_JJ and_CC second_JJ decades_NNS of_IN the_DT study_NN ._SENT Age-specific_JJ incidence_NN of_IN fungal_JJ BSIs_NN in_IN Iceland_NP from_IN 1980_CD to_TO 1999_CD calculated_VBN for_IN the_DT first_JJ and_CC second_JJ decades_NNS of_IN the_DT study_NN ._SENT As_IN shown_VBN ,_, the_DT age-specific_JJ incidence_NN was_VBD similarly_RB distributed_VBN in_IN the_DT first_JJ (_( open_JJ circles_NNS ,_, solid_JJ lines_NNS )_) and_CC the_DT second_JJ (_( filled_VBN circles_NNS ,_, dashed_VBD lines_NNS )_) decades_NNS ,_, with_IN the_DT exception_NN of_IN the_DT youngest_JJS age_NN group_NN (_( <1_JJ year_NN old_JJ )_) ._SENT The_DT incidence_NN was_VBD low_JJ in_IN people_NNS aged_VBN 5_CD to_TO 40_CD years_NNS but_CC started_VBD to_TO rise_VB among_IN people_NNS aged_VBN 41_CD to_TO 50_CD years_NNS ._SENT Incidence_NN subsequently_RB increased_VBN with_IN advancing_VBG age_NN ,_, peaking_VBG among_IN patients_NNS aged_VBN 61_CD to_TO 70_CD years_NNS (_( 1980_CD to_TO 1989_CD ,_, 12.7_CD cases/100,000_NN inhabitants/year_NN ;_: 1990_CD to_TO 1999_CD ,_, 19.3_CD cases/100,000_NN inhabitants/year_NN )_) ._SENT From_IN 1980_CD to_TO 1989_CD ,_, no_DT children_NNS of_IN <1_JJ year_NN of_IN age_NN were_VBD diagnosed_VBN with_IN candidemia_NN ._SENT After_IN 1989_CD ,_, however_RB ,_, the_DT incidence_NN followed_VBD a_DT biphasic_JJ pattern_NN ,_, with_IN a_DT high_JJ incidence_NN occurring_VBG in_IN the_DT youngest_JJS age_NN group_NN (_( <1_JJ year_NN ,_, 11.3_CD cases/100,000_NN inhabitants/year_NN )_) ._SENT Most_JJS of_IN the_DT children_NNS younger_JJR than_IN 1_CD year_NN old_JJ were_VBD preterm_NN infants_NNS in_IN the_DT neonatal_JJ ICU_NN at_IN the_DT time_NN of_IN diagnosis_NN ._SENT Table_NN shows_VBZ the_DT yeast_NN species_NN that_WDT were_VBD cultured_VBN from_IN the_DT blood_NN of_IN Icelandic_JJ patients_NNS from_IN 1980_CD to_TO 1999_CD ._SENT Species_NP distribution_NN remained_VBD relatively_RB stable_JJ in_IN the_DT country_NN ,_, with_IN C._NP albicans_NNS causing_VBG around_RP two-thirds_NNS of_IN infections_NNS (_( range_NN ,_, 63.4_CD to_TO 65.3_CD %_NN )_) and_CC Candida_NP non-albicans_NP species_NNS causing_VBG one-third_NN ._SENT There_EX was_VBD no_DT significant_JJ change_NN in_IN yeast_NN species_NNS distribution_NN between_IN the_DT first_JJ and_CC second_JJ halves_NNS of_IN the_DT study_NN (_( P_NN =_SYM 0.35_CD )_) ._SENT Species_NN identification_NN of_IN all_DT available_JJ isolates_NNS revealed_VBD Candida_NP dubliniensis_NN in_IN four_CD cases_NNS ._SENT TABLE_NN 1_CD |_SYM Yeast_NP strains_NNS isolated_VBN from_IN blood_NN cultures_NNS in_IN Iceland_NP from_IN 1980_CD to_TO 1999_CD The_DT MICs_NN of_IN amphotericin_NP B_NP ,_, fluconazole_NN ,_, and_CC itraconazole_NN were_VBD determined_VBN for_IN 99_CD strains_NNS dating_VBG from_IN 1991_CD to_TO 1999_CD ._SENT All_DT were_VBD susceptible_JJ to_TO amphotericin_NP B_NP (_( MIC_NP ,_, <=1_JJ mug/ml_NN )_) ,_, 97_CD %_NN were_VBD susceptible_JJ to_TO fluconazole_VB (_( MIC_NP ,_, <=8_NN mug/ml_NN )_) ,_, and_CC 87_CD %_NN were_VBD susceptible_JJ to_TO itraconazole_VB (_( MIC_NP ,_, <=0.125_NN mug/ml_NN )_) ._SENT During_IN the_DT study_NN period_NN ,_, the_DT number_NN of_IN isolates_NNS classified_VBN as_IN susceptible-dose_NN dependent_JJ for_IN itraconazole_NN increased_VBN from_IN 6.7_CD %_NN (_( 3_CD of_IN 45_CD )_) between_IN 1991_CD and_CC 1995_CD to_TO 16.7_CD %_NN (_( 9_CD of_IN 54_CD )_) between_IN 1996_CD and_CC 1999_CD ,_, but_CC this_DT increase_NN was_VBD not_RB statistically_RB significant_JJ ._SENT TABLE_NN 2_CD |_SYM In_IN vitro_NN susceptibility_NN of_IN 99_CD fungal_JJ BSIs_NN to_TO amphotericin_NP B_NP ,_, itraconazole_NN ,_, and_CC fluconazole_NN The_DT national_JJ import_NN of_IN antifungal_JJ agents_NNS from_IN 1990_CD to_TO 1999_CD is_VBZ shown_VBN in_IN Table_NP ._SENT Fluconazole_NP was_VBD approved_VBN for_IN oral_JJ and_CC parenteral_JJ use_NN in_IN 1990_CD ._SENT During_IN the_DT period_NN from_IN 1991_CD to_TO 1999_CD ,_, the_DT import_NN of_IN oral_JJ formulations_NNS increased_VBN from_IN 9.4_CD to_TO 47.6_CD DDD/1,000_NP inhabitants/year_NN (_( 406_CD %_NN )_) and_CC the_DT import_NN of_IN fluconazole_NN for_IN parenteral_JJ use_NN increased_VBN from_IN 0.5_CD to_TO 1.8_CD DDD/1,000_NP inhabitants/year_NN (_( 260_CD %_NN )_) ._SENT TABLE_NN 3_CD |_SYM National_JJ import_NN of_IN antifungal_JJ agents_NNS in_IN Iceland_NP from_IN 1990_CD to_TO 1999_CD expressed_VBN as_IN DDD_NN per_IN 1,000_CD inhabitants_NNS per_IN year_NN Several_JJ studies_NNS have_VBP shown_VBN a_DT substantial_JJ increase_NN in_IN the_DT incidence_NN of_IN candidemia_NN in_IN the_DT past_JJ 2_CD decades_NNS ._SENT Data_NNS from_IN the_DT NNIS_NP system_NN on_IN nosocomial_JJ BSIs_NN showed_VBD an_DT up_RP to_TO fivefold_JJ increase_NN in_IN incidence_NN between_IN 1980_CD and_CC 1989_CD in_IN the_DT United_NP States_NPS ._SENT According_VBG to_TO another_DT surveillance_NN study_NN from_IN the_DT NNIS_NP program_NN ,_, between_IN 1995_CD and_CC 1996_CD Candida_NP species_NNS was_VBD the_DT fourth_JJ most_RBS common_JJ cause_NN of_IN nosocomial_JJ BSI_NP ._SENT Our_PP$ data_NNS show_VBP that_IN the_DT incidence_NN of_IN candidemia_NN in_IN Iceland_NP has_VBZ increased_VBN steadily_RB and_CC significantly_RB over_IN the_DT past_JJ 2_CD decades_NNS ._SENT The_DT incidence_NN is_VBZ somewhat_RB higher_JJR than_IN that_DT documented_VBN in_IN a_DT nationwide_JJ study_NN in_IN Norway_NP from_IN 1991_CD to_TO 1996_CD (_( an_DT average_NN of_IN 0.17_CD per_IN 1,000_CD discharges_NNS )_) but_CC similar_JJ to_TO that_WDT observed_VBD in_IN Israel_NP in_IN 1994_CD (_( 0.50_CD per_IN 1,000_CD admissions_NNS )_) ._SENT Although_IN the_DT use_NN of_IN blood_NN cultures_NNS increased_VBN at_IN the_DT university_NN hospitals_NNS ,_, the_DT proportion_NN of_IN cultures_NNS that_WDT turned_VBD out_RP positive_JJ for_IN yeasts_NNS remained_VBD stable_JJ ._SENT The_DT observed_JJ increase_NN may_MD be_VB due_JJ in_IN part_NN to_TO improved_VBN detection_NN ,_, but_CC other_JJ factors_NNS are_VBP likely_JJ to_TO have_VB played_VBN a_DT role_NN ._SENT Among_IN them_PP are_VBP the_DT greater_JJR use_NN of_IN invasive_JJ devices_NNS and_CC broad-spectrum_NN antibacterial_NN agents_NNS ,_, more_JJR extensive_JJ surgical_JJ procedures_NNS ,_, and_CC advanced_JJ life_NN support_NN ._SENT The_DT length_NN of_IN stay_NN at_IN the_DT university_NN hospitals_NNS in_IN Iceland_NP ,_, where_WRB 87_CD %_NN of_IN the_DT patients_NNS were_VBD diagnosed_VBN ,_, did_VBD not_RB increase_VB in_IN the_DT past_JJ 2_CD decades_NNS and_CC therefore_RB does_VBZ not_RB explain_VB our_PP$ findings_NNS ._SENT Many_JJ studies_NNS on_IN the_DT epidemiology_NN of_IN fungal_JJ BSIs_NN have_VBP focused_VBN on_IN selected_JJ hospitals_NNS or_CC hospital_NN wards_NNS ,_, with_IN different_JJ patient_JJ populations_NNS ,_, and_CC have_VBP reported_VBN a_DT substantially_RB higher_JJR incidence_NN than_IN is_VBZ reported_VBN in_IN this_DT study_NN ._SENT According_VBG to_TO two_CD studies_NNS on_IN candidemia_NN ,_, one_CD in_IN Australia_NP and_CC one_CD in_IN the_DT United_NP States_NPS ,_, the_DT incidence_NN was_VBD 1.5_CD and_CC 3.3_CD episodes_NNS per_IN 1,000_CD discharges_NNS ,_, respectively_RB ._SENT Another_DT study_NN at_IN the_DT M.D._NP Anderson_NP Cancer_NP Center_NP reported_VBD an_DT incidence_NN of_IN 6_CD cases_NNS of_IN fungemia_NN per_IN 1,000_CD admissions_NNS between_IN 1988_CD and_CC 1992_CD ._SENT A_DT prospective_JJ multicenter_NN study_NN of_IN candidemia_NN at_IN six_CD sites_NNS in_IN the_DT United_NP States_NPS concluded_VBD that_IN the_DT incidence_NN was_VBD 9.8_CD cases/1,000_JJ admissions_NNS in_IN surgical_JJ intensive_JJ care_NN units_NNS (_( ICUs_NP )_) and_CC 12.3_CD cases/1,000_JJ admissions_NNS in_IN neonatal_JJ ICUs_NP ._SENT Studies_NNS on_IN candidemia_NN and_CC pathogen_NN species_NNS distribution_NN from_IN different_JJ parts_NNS of_IN the_DT world_NN generally_RB agree_VBP that_IN C._NP albicans_NNS is_VBZ still_RB the_DT most_RBS commonly_RB isolated_VBN fungal_JJ pathogen_NN from_IN blood_NN ,_, causing_VBG between_IN 50_CD and_CC 70_CD %_NN of_IN infections_NNS ._SENT According_VBG to_TO our_PP$ data_NNS ,_, approximately_RB two-thirds_NNS (_( 64.4_CD %_NN )_) of_IN fungal_JJ BSIs_NN in_IN Iceland_NP were_VBD caused_VBN by_IN C._NP albicans_NNS and_CC one-third_NN were_VBD caused_VBN by_IN Candida_NP non-albicans_NP species_NNS ._SENT These_DT results_NNS are_VBP comparable_JJ to_TO those_DT reported_VBN from_IN Norway_NP but_CC somewhat_RB higher_JJR than_IN those_DT reported_VBN from_IN the_DT United_NP States_NPS ,_, Canada_NP ,_, Latin_NP America_NP ,_, and_CC Europe_NP ._SENT Among_IN the_DT different_JJ fungal_JJ species_NNS ,_, we_PP identified_VBD C._NP dubliniensis_NN as_IN the_DT pathogen_NN in_IN four_CD cases_NNS ._SENT This_DT species_NN ,_, which_WDT was_VBD originally_RB described_VBN by_IN Sullivan_NP and_CC coworkers_NNS in_IN 1995_CD ,_, is_VBZ germ_NN tube_NN positive_JJ and_CC can_MD therefore_RB easily_RB be_VB mistaken_VBN for_IN C._NP albicans_NNS ._SENT The_DT proportion_NN of_IN candidemias_NNS caused_VBN by_IN Candida_NP non-albicans_NP has_VBZ not_RB increased_VBN in_IN the_DT past_JJ 20_CD years_NNS according_VBG to_TO our_PP$ results_NNS ._SENT In_IN contrast_NN ,_, other_JJ studies_NNS have_VBP reported_VBN a_DT shift_NN towards_IN Candida_NP non-albicans_NP species_NNS in_IN the_DT past_JJ 5_CD to_TO 10_CD years_NNS ._SENT Antifungal_JJ prophylaxis_NN with_IN fluconazole_NN may_MD have_VB played_VBN a_DT role_NN in_IN this_DT observed_JJ shift_NN ._SENT In_IN two_CD studies_NNS ,_, fluconazole_NN prophylaxis_NN was_VBD the_DT single_JJ most_RBS important_JJ determinant_NN for_IN the_DT relative_JJ increase_NN in_IN Candida_NP krusei_NP and_CC Candida_NP glabrata_NN infections_NNS ._SENT Fluconazole_NN prophylaxis_NN is_VBZ used_VBN infrequently_RB in_IN Iceland_NP ,_, which_WDT may_MD explain_VB this_DT difference_NN ._SENT The_DT antifungal_JJ susceptibility_NN patterns_NNS revealed_VBD that_IN 97_CD %_NN of_IN the_DT Icelandic_JJ strains_NNS were_VBD susceptible_JJ to_TO fluconazole_NN ,_, despite_IN an_DT approximately_RB fourfold_JJ increase_NN in_IN fluconazole_NN import_NN in_IN the_DT past_JJ decade_NN ._SENT Little_NP has_VBZ been_VBN published_VBN about_IN national_JJ consumption_NN of_IN antifungal_JJ agents_NNS ._SENT Our_PP$ results_NNS can_MD be_VB compared_VBN to_TO data_NNS from_IN the_DT study_NN conducted_VBN in_IN Norway_NP ,_, where_WRB the_DT use_NN of_IN fluconazole_NN increased_VBN from_IN 8.0_CD to_TO 16.1_CD DDD/1,000_NN inhabitants/year_NN between_IN 1991_CD and_CC 1996_CD ._SENT During_IN the_DT same_JJ period_NN ,_, a_DT greater_JJR increase_NN in_IN fluconazole_NN import_NN was_VBD seen_VBN in_IN Iceland_NP :_: from_IN 9.9_CD to_TO 24.9_CD DDD/1,000_NP inhabitants/year_NN ._SENT The_DT use_NN of_IN amphotericin_NP B_NP remained_VBD relatively_RB stable_JJ ._SENT In_IN conclusion_NN ,_, this_DT study_NN has_VBZ shown_VBN that_IN ,_, on_IN a_DT national_JJ level_NN ,_, the_DT incidence_NN of_IN candidemia_NN in_IN Iceland_NP has_VBZ increased_VBN 3.5-fold_NN over_IN the_DT past_JJ 2_CD decades_NNS ,_, with_IN the_DT highest_JJS incidences_NNS of_IN infection_NN occurring_VBG in_IN the_DT youngest_JJS and_CC older_JJR age_NN groups_NNS ._SENT The_DT proportion_NN of_IN infections_NNS caused_VBN by_IN Candida_NP non-albicans_NP species_NN has_VBZ remained_VBN stable_JJ ._SENT Fluconazole_NN use_NN has_VBZ increased_VBN approximately_RB fourfold_RB in_IN the_DT past_JJ decade_NN ,_, but_CC the_DT majority_NN of_IN strains_NNS are_VBP still_RB susceptible_JJ to_TO this_DT agent_NN ._SENT 